Tocilizumab and adalimumab were used in patients with JIA or in cases of systemic inflammation characterized by elevated serum interleukin-6 (IL-6) or tumor necrosis factor-alpha (TNF-α) levels, respectively. This evidence concerns the gene TNF and juvenile idiopathic arthritis.